ctDNA Testing May Provide Sufficient Accuracy For Widespread Adoption In Routine Clinical Practice To Identify Patients With Breast Cancer Suitable For Targeted Therapies Cancer Network (9/17, Slater) reports researchers found in a phase 2a trial “that circulating tumor DNA (ctDNA) testing provides sufficient accuracy for widespread adoption in routine clinical practice to identify patients with breast cancer […]
Medscape (9/10, Fuerst, Subscription Publication) reports all patients with breast cancer “who develop a second primary cancer should undergo multigene panel testing, according to a paper published in JCO Precision Oncology.” The paper’s “authors noted that women with breast cancer have a 4%-16% lifetime risk of a second primary cancer,” but “it hasn’t been clear if […]
Forbes (9/7, Broster) reports that “September marks Gynecological Cancer Awareness Month,” and “according to a new study, 78% of people were unaware of the five different gynecological cancers and 86% didn’t know what symptoms to look out for.” In the study, researchers spoke to 100 women between the ages of 18 and 44, and found “44% […]
Women With Recurrent Ovarian Cancer With Maintenance Use Of Rucaparib May Have Longer Quality-Adjusted PFS And Quality-Adjusted Time Without Symptoms Or Toxicity Compared To Placebo Cancer Therapy Advisor (9/3, Moench) reports researchers conducted an exploratory analysis and found “longer quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity in women with recurrent ovarian cancer […]